Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.064 AUD | +4.92% | +6.67% | -9.86% |
04-04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
02-27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Sales 2022 | 5.43M 3.55M 284M | Sales 2023 | 6.01M 3.93M 314M | Capitalization | 12.57M 8.21M 657M |
---|---|---|---|---|---|
Net income 2022 | -18M -11.76M -941M | Net income 2023 | -15M -9.8M -784M | EV / Sales 2022 | 7.95 x |
Net cash position 2022 | 13.85M 9.05M 724M | Net cash position 2023 | 3.01M 1.97M 157M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
1 day | +4.92% | ||
1 week | +6.67% | ||
Current month | -4.48% | ||
1 month | +4.92% | ||
3 months | -1.54% | ||
6 months | -33.33% | ||
Current year | -9.86% |
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 28/02/19 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 07/05/20 |
Peter Marks
BRD | Director/Board Member | 68 | 14/03/16 |
Boris Patkin
BRD | Director/Board Member | - | 25/03/20 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.064 | +4.92% | 59,631 |
22/04/24 | 0.061 | +1.67% | 15,505 |
19/04/24 | 0.06 | -3.23% | 215,468 |
18/04/24 | 0.062 | +3.33% | 12,401 |
Delayed Quote Australian S.E., April 26, 2024 at 04:37 am
More quotes1st Jan change | Capi. | |
---|---|---|
-9.86% | 12.2M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- NOX Stock